- Home
- JPC vs APLS Comparison
JPC vs APLS Comparison
Compare JPC & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JPC
- APLS
- Stock Information
- Founded
- JPC 2003
- APLS 2009
- Country
- JPC United States
- APLS United States
- Employees
- JPC N/A
- APLS N/A
- Industry
- JPC Investment Managers
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- JPC Finance
- APLS Health Care
- Exchange
- JPC Nasdaq
- APLS Nasdaq
- Market Cap
- JPC 2.9B
- APLS 2.9B
- IPO Year
- JPC N/A
- APLS 2017
- Fundamental
- Price
- JPC $8.10
- APLS $30.05
- Analyst Decision
- JPC
- APLS Buy
- Analyst Count
- JPC 0
- APLS 19
- Target Price
- JPC N/A
- APLS $33.63
- AVG Volume (30 Days)
- JPC 998.5K
- APLS 2.4M
- Earning Date
- JPC 01-01-0001
- APLS 10-30-2025
- Dividend Yield
- JPC 7.57%
- APLS N/A
- EPS Growth
- JPC N/A
- APLS N/A
- EPS
- JPC N/A
- APLS N/A
- Revenue
- JPC N/A
- APLS $754,649,000.00
- Revenue This Year
- JPC N/A
- APLS $24.62
- Revenue Next Year
- JPC N/A
- APLS N/A
- P/E Ratio
- JPC N/A
- APLS N/A
- Revenue Growth
- JPC N/A
- APLS 20.02
- 52 Week Low
- JPC $5.94
- APLS $16.10
- 52 Week High
- JPC $7.36
- APLS $35.72
- Technical
- Relative Strength Index (RSI)
- JPC 53.55
- APLS 70.16
- Support Level
- JPC $8.06
- APLS $23.85
- Resistance Level
- JPC $8.15
- APLS $30.48
- Average True Range (ATR)
- JPC 0.06
- APLS 1.23
- MACD
- JPC 0.00
- APLS 0.55
- Stochastic Oscillator
- JPC 56.39
- APLS 94.78
About JPC Nuveen Preferred & Income Opportunities Fund
Nuveen Preferred & Income Opportunities Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. It invests its managed assets in preferred securities, and in other types of securities, primarily income-oriented securities such as corporate and taxable municipal debt and common equity.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.